查看文章

Radioligand therapy (RLT) with ¹⁷⁷Lu-PSMA-617 (PSMA is prostate-specific membrane antigen) is a novel targeted therapy for metastatic prostate cancer. In this study, we evaluated the effect of different pretherapeutic parameters on the therapeutic response measured by prostate-specific antigen (PSA) 2 mo after RLT. RLT was performed in 40 hormone-refractory patients with distant metastases and progressive disease (mean age, 71.4 y). ⁶⁸Ga-PSMA-11 PET/CT was performed in all patients 1–2 wk before RLT. All patients were treated with a mean of 6 GBq. The SUV_max of tumor lesions was determined using region-of-interest analysis. Complete blood counts, renal and liver function assessments, previous therapies, pain medication, and SUVs were included in the analysis. PSA was assessed 2 mo after RLT. In the univariate analysis, younger age, higher levels of γ-glutamyl transferase …